Special Issue "Zebrafish: The Key for Cancer Treatment"
Deadline for manuscript submissions: closed (31 August 2017)
Zebrafish has been used since the early 1970s in Oregon as a model organism for vertebrate development and gene function. Over the past few years, zebrafish has emerged as a cancer model that complements the murine system. This model was discovered in cancer research with cancer currently being the second cause of death worldwide. It has been increasingly used in subsequent years due to the exponential growth of cancer, especially in developed countries. By virtue of its experimental swiftness, low cost maintenance and high-throughput advantages against the murine model, the zebrafish has had a high impact on research.
Covering areas ranging from biochemistry or genetics, to toxicology or xenotransplantation, zebrafish is a useful tool to discover some of the most important underlying mechanisms of cancer proliferation, migration and metastasis. Using this small fish, researchers from all over the world are able to gather information in a very efficient way to fight against this heterogeneous disease.
In this Special Issue, we would like to invite submissions of original research or review articles on any topic related to “Zebrafish: The Key for Cancer Treatment”. We thereby hope to gather knowledge to find critical steps for cancer treatment using this model organism. We look forward to receiving your contributions.
Dr. Laura Sánchez
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- model organism
- high throughput
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Working Title: A versatile transgenic zebrafish recapitulates genetic, proteomic and histological features of Ewing sarcoma: New model for drug discovery.
Putative Authors: Wietske van der Ent1,2, Dana Ohana3 Peter J. Schoonheim1, Karoly Szuhai3, Herman P. Spaink1, Pancras C.W. Hogendoorn2, Magnus Palmblad3 , B. Ewa Snaar-Jagalska1*
Affiliations: 1Institute of Biology, Leiden University, Leiden, The Netherlands , 2Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands, 3Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, The Netherlands
Abstract: Ewing sarcoma, a highly malignant bone and soft-tissue tumour, is characterized by a translocation between EWSR1 and a member of the ETS family, most commonly FLI1 or ERG. Despite knowledge of this key feature of Ewing sarcoma, so far no transgenic mouse models have been established that can accurately recapitulate this disease, as all attempts have led to embryonic death. The exact cell of origin for Ewing sarcoma is unknown, which confounds determination of a promoter suitable to drive EWSR1-ETS expression. Here, we have generated a zebrafish transgenic model for Ewing sarcoma where expression of GFP-tagged EWSR1-ERG protein is driven by a Gal4-responsive UAS promoter. By crossing Tg(14xUAS:GFP-EWSR1-ERG) fish with various transgenic driver lines expressing Gal4 via specific tissue-specific promoters, we observed that neuronal cells are more permissive of EWSR1-ERG expression than cells in the notochord or muscles of the fish. Histology shows that these transgenic cells have round nuclei and scant cytoplasm, bearing a resemblance to cell features of human EWS tumour biopsies. Using next generation sequencing and comparative LC-MS/MS proteomics analysis on embryos with neuronally expressed EWSR1-ERG, we show regulation of various pathways known to be transcriptionally regulated in EWS, such as the downregulation of the Notch pathways, as well as other pathways which may be of interest. The zebrafish Tg(14xUAS:GFP-EWSR1-ERG) line provides a flexible method to investigate the effects of EWSR1-ERG expression in different background tissues and is a promising tool to study processes involved in Ewing sarcoma development and testing potential treatments.
Working Title: Finding novel cancer therapies using zebrafish.
Putative Authors: Aurora Idilli, Francesca Precazzini, Marina Mione and Viviana Anelli
Affiliations: Laboratory of Experimental Cancer Biology, Cibio, University of Trento, Via Sommarive 9, Trento, Italy
Abstract: Over the past 15 years, zebrafish has emerged as a powerful tool for studying human cancers. Transgenic techniques have been employed to model leukemia, rhabdomyosarcoma, melanoma and glioblastoma. These models present histopathological and molecular conservation with their human cancer counterparts and have been fundamental for understanding mechanisms of tumor initiation and progression. Moreover, xenotrasplantations of human cancer cells in embryos, juvenile or adults zebrafish offer the advantage of studying the behavior of human cancer cells in a live organism. Chemical-genetic screens using zebrafish embryos have uncovered novel drug pathways and new therapeutic strategies, some of which are now tested in clinical trials.
Working Title: Emerging estrogenic pollutants in the aquatic environment and breast cancer.
Putative Authors: Sylvain Lecomte, Denis Habauzit, Farzad Pakdel*
Affiliations: Research Institute in Health, Environment and Occupation (Irset), Inserm U1085, Team TREC-Transcription, Environment and Cancer, University of Rennes 1, France
*Corresponding Author: Farzad PAKDEL (firstname.lastname@example.org)
Abstract: Over the past five decades, the number of industrial chemicals in the aquatic environment has considerably increased. Among these contaminants, endocrine disrupting chemicals (EDCs) represent a significant part. These kind of compounds interfere with normal hormonal processes through multiple molecular pathways. They represent therefore a potential risk for human and wildlife as they are suspected to be involved in the development of diseases such as reprotoxicity, metabolic disorders and cancers. Indeed, several studies have suggested that the increase of breast cancer in industrialized country are linked to EDCs, particularly estrogen-like compounds. In cell, estrogen receptors (ERs, ERalpha and ERbeta) are the main targets of these compounds. More than 70% of breast cancer cells express ERalpha and their growth is influenced by estrogenic compounds. It is therefore important to characterize the estrogenic potential in surface water and to identify the molecules responsible for the hormonal effect. This would give us the possibility to prevent their effects on the breast tissue. The aim of this review is to make an overview of the emerging environmental estrogen-like compounds in the environment, to sum up the studies that evidence their direct or indirect interactions with ERs and their potential involvement in breast cancer development. Finally, we also summarize the use of in vitro and in vivo methods and models such as zebrafish, in the identification and characterization of environmental estrogens.
Working Title: The zebrafish as a model for skin cancer: a new tool for drug development.
Putative Authors: Carlo Pincelli, Annalisa Saltari and Elisabetta Palazzo
Affiliations: School of Medicine, University of Modena and Reggio Emilia, Modena, Italy
Abstract: Danio rerio, commonly known as zebrafish, is considered a promising model for the study of the mechanisms underlying tumor development, treatment efficacy and drug resistance. Given the advantages in terms of low costs, high genetic homology to humans, easy handling and transparent body for live imaging, the zebrafish has been employed to study and reproduce a broad spectrum of human tumours, including melanoma and squamous cell carcinoma (SCC). The zebrafish models for cutaneous neoplasia have been generated with different strategies including injection of cancer cells, tumour induction through chemical carcinogens and genetic manipulation. Exciting data have been recently published in melanoma by using the innovative genome-engineering Crispr/Cas9 (clustered regularly interspaced short palindromic repeats) and TALENs (transcription activator-like effectors) technologies. In the last decades, the acquisition of new genetic and transcriptomic data has led to the identification of potential targets for the treatment of skin cancer prompting the need of in vivo models for toxicological tests on large scale. To this purpose, given its higher fecundity in comparison to mouse models, the zebrafish represents an ideal tool for high-throughput drug screening. The present review focuses on the applications of zebrafish for the study of melanoma and SCC and summarizes the main findings on skin cancer initiation, relapse and drug resistance. Moreover, it highlights the progress and future perspectives for its employment as an innovative platform for the screening of small molecules and compounds.
Working Title: RecQ1 helicase silencing slows proliferation of U87 glioblastoma cells in the zebrafish embryonic brain.
Putative Authors: Katja Hrovat1, Miloš Vittori2, Tamara Lah Turnšek1
Affiliations: 1 National Institute of Biology, Ljubljana, Slovenia
2 Department of Biology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia
Abstract: In this study, the proliferation of U87 cells in which the expression of RecQ1 helicase has been experimentally reduced is compared to the proliferation of sham-transfected U87 cells. In vitro measurments of cell proliferation are compared with in vivo measurments in the brain and yolk sac of zebrafish embryos during a three-day period. Decreased proliferation was observed in vitro as well as in the zebrafish brain, whereas U87 cells do not readily proliferate in the yolk sac, resulting in no visible effect of RecQ1 depletion. This is the first in vivo confirmation of RecQ1 as a potential therapeutic target in the treatment of glioblastoma.
Working Title: Co-implantation with glioblastoma stem-like cells influences the invasion of U87 glioblastoma cells in zebrafish embryos.
Putative Authors: Miloš Vittori1, Barbara Breznik2, Tamara Lah Turnšek2
Affiliations: 1 Department of Biology, Biotechnical Faculty, University of Ljubljana, Ljubljana, Slovenia
2 National Institute of Biology, Ljubljana, Slovenia
Abstract: We assessed the proliferation and invasion of U87 cells and the CD133+ glioblastoma stem-like cell line NCH421k in the brain of zebrafish embryos. Our results demonstrate that the co-implantation of both cell types strongly affects the invasion of U87 cells, quantified by measurements of relative cell dispersion and the frequency of invading cells, whereas it does not affect the invasion of NCH421k cells. The two cell lines are inhomogeneously distributed in the tumours, with each cell type occupying a well defined region of the tumour. These results are compared with the behaviour of U87 cells when co-implanted with mesenchymal stem cells.